pharma · Infertility in women undergoing assisted reproductive technologies (ART) · Intermediate risk, non-muscle invasive bladder cancer
Ferring Pharmaceuticals
Ferring Pharmaceuticals is a pharma organization headquartered in Mumbai, IN. Primary therapeutic focus areas include Infertility in women undergoing assisted reproductive technologies (ART), Intermediate risk, non-muscl
Company details
- Status
- Public
- HQ
- -, St-Prex, 1162, CH, Mumbai
- Founded
- 1950
- Employees
- 6,228
- Programs
- 13
- Drugs
- 23
- Patents
- 0
000434
Phase 3 · small molecule · High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ(CIS) with or without papillary tumours
000434 for High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ(CIS) with or without papillary tumours is a Phase 3 program (small_molecule) at Ferring Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code 000434
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Ferring Pharmaceuticals
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ(CIS) with or without papillary tumours
- Status
- active
- Trials
- 1